Treatment for Hepatitis C Virus Infection in Adults: Comparative Effectiveness
Response Rates in Patients With HCV Genotype 2 or 3 Infection According to Duration of Dual Therapy
Four trials of patients with hepatitis C virus (HCV) genotype 2 or 3 infection found that 24 weeks of dual therapy with ribavirin plus pegylated interferon alfa-2a or with ribavirin plus pegylated interferon alfa-2b was more effective when compared with 12–16 weeks of dual therapy for achieving a sustained virologic response (SVR; pooled relative risk [RR], 1.2; 95-percent confidence interval [95% CI], 1.0 to 1.3). Absolute SVR rates after 24 weeks of dual therapy ranged from 67–78 percent, while SVR rates after 12–16 weeks of dual therapy ranged from 57–62 percent. The strength of evidence for this finding was rated moderate.
Three trials of patients with HCV genotype 2 or 3 infection who achieved a rapid virologic response (defined as undetectable HCV RNA by week 4 of treatment) found no difference between patients randomized to a total of 24 weeks of dual therapy versus 12–16 weeks of dual therapy (pooled RR, 0.99; 95% CI, 0.86 to 1.14). The strength of evidence for this finding was rated moderate.
Keywords: finding | outcome | hepatitis C | HCV | treatment | dual therapy | genotype | strength of evidence
- Chou R, Hartung D, Rahman B, et al. Treatment for Hepatitis C Virus Infection in Adults: A Comparative Effectiveness Review. Evidence Report No. 76 (Prepared by the Oregon Evidence-based Practice Center under Contract No. 290-2007-10057-I). Rockville, MD: Agency for Healthcare Research and Quality; August 2012. AHRQ Publication No. 12-EHC113-EF. Available at www.effectivehealthcare.ahrq.gov/hepctreatment.cfm.
Your slide tray is being processed.